The overarching purpose of this funding opportunity announcement (FOA) in Central Asia- Tajikistan is to fund activities intended to enhance the capacity of RBC to scale up and improve the quality of the blood safety program within all the areas of Tajikistan and to improve access of the general population to safe, high quality blood components. The CDC program goal relevant to this FOA in Tajikistan is to strengthen the capacity of the RBC staff to expand access to safe, high quality blood products. Through this FOA, the RBC will participate in a project to: * Develop and implement an effective program for development of the VNRB system; * Rationalize clinical use of blood components; * Improve the quality management system via implementation of an M&E tool for indicators of blood services performance and automation of the work processes in the chain from vein-to vein; and * Improve the cold chain within the entire national blood service.
This Funding Opportunity Announcement (FOA) encourages research grant applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Research focused on improving blood donor health, the safety and availability of blood products, and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs.
This Funding Opportunity Announcement (FOA) encourages research grant applications from investigators who propose to study research topics in blood banking and transfusion medicine aimed at improving the safety and availability of the blood supply and the practice of transfusion medicine. Research focused on improving blood donor health, the safety and availability of blood products, and improving the practice of transfusion medicine is critical to public health. Research designed to better understand the determinants of transfusion-associated adverse events and how best to minimize transfusion risks is also important. Research is also needed to maintain an adequate blood supply by minimizing the risks associated with the donation process and developing enhanced recruitment and retention programs.
The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (K99) is to increase and maintain a stong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. Applicants who receive this award may submit an application for R00 funding, in the separate funding opportunity associated with this program, to help awardees to launch competitive, independent research careers in blood science. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial , as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA (RFA-HL-20-001).
The purpose of the NHLBI Career Pathway to Independence in Blood Science Award for Physician Scientists (K99) is to increase and maintain a strong cohort of new and talented, NHLBI supported, independent investigators in blood science. This program is designed to facilitate a timely transition of outstanding blood science researchers with a clinical doctorate degree from mentored research positions to independent, tenure-track or equivalent faculty positions. Applicants who receive this award may submit an application for R00 funding, in the separate funding opportunity associated with this program, to help awardees launch competitive, independent research careers in blood science.
The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. This Funding Opportunity Announcement (FOA) will solicit research projects focused on the development of new technology and tools, or novel mechanistic studies, or a combination of mechanistic and technology development studies specific to central nervous system (CNS, which includes retina) small blood and lymphatic vessels in health and disease, across the life span. The program aims at facilitating the development of tools and technology to image, profile and map CNS small blood and lymphatic vessels. Additional goals are to elucidate the mechanisms underlying CNS small blood and lymphatic vessels structural and functional heterogeneity, differential susceptibility to injury, role in disease and repair processes, and their responses to therapies. Preclinical studies using in vitro and/or animal models specific to CNS small blood and lymphatic vessels alone or in combination with pilot human studies are appropriate for this FOA.
The 2014-2016 Ebola Virus Disease (EVD) outbreak in Liberia exposed the acute vulnerability of Liberia's public health system. Limited laboratory capacity and resources, including lack of diagnostic capacities to test for infectious diseases, an unreliable blood supply with inadequate blood services, and poor to non-existent infection prevention and control (IPC) resources and practices in health facilities and laboratories left the Liberian health system unprepared for the EVD outbreak. Significant investments and gains have been made since 2014 to strengthen Liberia's public health system; however, the system remains fragile. The US Centers for Disease Control and Prevention (CDC), in coordination with the Government of Liberia (GOL) and local and international partners, continues to support health system strengthening activities, further building Liberia's capacity to prevent, detect, and respond to disease outbreaks at their source. This NOFO supports activities to strengthen laboratory capacities, further developing a competent laboratory workforce and expanding diagnostic capacities, reinforced through laboratory quality management activities; improved blood transfusion practices to build and maintain quality blood transfusion services; and strengthening infection prevention and control practices, with the goal of reducing transmission of epidemic prone diseases and antimicrobial resistance within healthcare facilities. These activities align with Global Health Security Agenda priorities in preventing, detecting and responding to potential public health threats. In order to continue efforts to maintain and expand Liberia's capabilities to prevent, detect, and respond to potential infectious disease outbreaks, CDC, the GOL, and partners must work to ensure a rapid diagnosis of infectious diseases.
Blood disorders are causes of morbidity and mortality, affecting one in 76 people in the United States (US). Hemophilia, von Willebrand disease (VWD), venous thromboembolism (VTE), and thalassemia are the blood disorders addressed within three separate components in this notice of funding opportunity (NOFO). The purpose of this NOFO is to provide credible health information and evidence-based training as well as to support the implementation and evaluation of evidence-based health promotion and education programs. The health promotion framework will be used to ensure early identification, intervention, and management to improve outcomes for people with blood disorders. Applicants would apply to only one of the three following blood disorder components: 1) Hemophilia and VWD or 2) VTE or 3) Thalassemia.
PEPFAR South Sudan works in collaboration with the Government of South Sudan (GOSS) Ministry of Health (MOH) in implementing the HIV/AIDS National Strategic Plan (NSP) based on a priority action approach and strong collaboration and coordination among different stakeholders. PEPFAR South Sudan has prioritized supporting the MOH in strengthening their national laboratory system with the primary objective of supporting the diagnosis, treatment, prevention and surveillance of HIV through high-quality laboratory services. This funding opportunity announcement (FOA) solicits technical assistance (TA) to strengthen the GOSS MOH laboratory and blood transfusion services systems. Outcomes will include the overall strengthening of the National Reference Lab, implementing and achieving accreditation for quality assurance systems; strengthening service delivery through increased technical assistance to lab testing programs, and training and accreditation for the national blood safety programs. The ultimate outcome is a national integrated quality-assured network of tiered laboratories providing quality clinical laboratory services with the capacity to support the diagnosis, treatment, prevention and surveillance of HIV and other diseases and support the establishment of the National Public Health Laboratory (NPHL) and the National Blood Transfusion Services (NBTS).
This NOFO aims to improve access to, coordination of, and continuity of health care for individuals with thalassemia or sickle cell disease which will lead to a decreased occurrence of transfusion-related complications, improved quality and increased length of life. These health care improvements will result from a multi-faceted approach that includes (1) identification of patients, families, communities, and providers who will benefit from increased knowledge about therapeutic transfusions and their potential complications, (2) development and dissemination of materials that will increase understanding of the diagnosis and management of these blood disorders, and (3) collection of biological specimens from individuals with thalassemia or sickle cell disease. This NOFO builds upon findings from the work completed as part of CDC-RFA-DD14-1406. In particular, (1) the difficulty in identifying any thalassemia patient in the U.S. and their health care provider prior to medical complications manifesting, other than those born in states where the condition is a part of the mandatory newborn screening panel, (2) the lack of standardized practices across, and sometimes within, clinical care settings and blood banks for transfusions of patients with thalassemia or sickle cell disease, (3) the need for dissemination of evidence- or consensus-based guidelines about best practices for transfusions, and (4) the room for improvement in increasing blood donation from communities most affected by thalassemia or sickle cell disease.
The purpose of this Funding Opportunity Announcement (FOA) is to support new and innovative epidemiology research in heart, lung, blood, and/or sleep diseases, disorders, and/or phenotypes. Through this FOA, the National Heart, Lung, and Blood Institute (NHLBI) aims to establish a new epidemiology cohort of at least 2000 participants to stimulate research on a wide range of heart, lung, blood, and/or sleep research hypotheses.
The NIH Blueprint for Neuroscience Research is a collaborative framework through which 14 NIH Institutes, Centers and Offices jointly support neuroscience-related research, with the aim of accelerating discoveries and reducing the burden of nervous system disorders. This Funding Opportunity Announcement (FOA) will solicit research projects to facilitate the development and translation of tools and technology for non-invasive imaging and profiling of human central nervous system (CNS, including retina) small blood and lymphatic vessels; to investigate their role in CNS physiology, disease, repair processes, and responses to therapy using novel approaches. Applications can be focused on the development of new technology and tools, novel target or biomarker identification and validation studies, or a combination of mechanistic and technology development studies specific to human CNS small blood and lymphatic vessels in health and disease, across the life span.
The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications to establish new and innovative epidemiology cohort studies that will prospectively follow at least 2,000 participants and are designed to study a wide range of research hypotheses related to heart, lung, blood, and/or sleep phenotypes. Through this FOA, the National Heart, Lung, and Blood Institute (NHLBI) will support activities required to establish a new cohort, including identification and recruitment of cohort participants, detailed baseline data collection on all participants, biospecimen collection and storage, study infrastructure, and data quality control and analysis.
This Funding Opportunity Announcement (FOA) seeks grant applications for a Research Coordinating Center (RCC) to support associated "Heart, Lung, and Blood Co-morbiditieS Implementation Models in People Living with HIV (HLB SIMPLe)" UG3/UH3 phased cooperative agreements that propose to optimally and sustainably address late-stage implementation research questions to address the delivery of proven-effective prevention and treatment interventions for heart, lung, blood, and sleep (HLBS) comorbid diseases and disorders in people living with HIV (PLHIV) in World Bank designated low- and middle-income countries (LMICs) and Small Island Developing States (SIDS). For the purposes of this FOA, late-stage implementation research is defined as research to identify strategies to achieve sustainable uptake of proven-effective interventions in routine clinical, public health, and community-based settings and maximize the positive impact on population health. The RCC will coordinate the collaborative efforts of the global alliance of funded UG3/UH3 phased cooperative agreements conducting late-stage implementation research within the following geographical regions: East Asia and the Pacific, Europe and Central Asia, Latin America and the Caribbean, Middle East and North Africa, South Asia, and Sub-Saharan Africa. The HLB SIMPLe RCC will coordinate activities including in-person and virtual Network Steering Committee meetings, subcommittee meetings, and working groups; promote collaboration and communication among investigators and the broader research community; coordinate network outreach activities; coordinate joint research and capacity building efforts conducted across the HLB SIMPLe alliance; and organize, implement, and manage a global implementation research data safety and monitoring board (DSMB).
Also listed under UG3/UH3
The purpose of this cooperative agreement is to expand upon the work of the Registry and Surveillance for Hemoglobinopathies (RuSH) project so as to address the new Healthy People 2020 topic, Blood Disorders and Blood Safety. This will be a demonstration project addressing two areas of Public Health: surveillance and health promotion and prevention awareness. Applicants are encouraged to assemble strategies that both strengthen their current capacities and develop innovative approaches to accomplish the objectives of this program.
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing research on the use of current and emerging technologies for monitoring of blood glucose levels to capture the relationship between blood glucose excursions, perception of wellbeing, and cognitive status in people with type 1 diabetes (T1D). This information will inform the design of more effective interventions that may improve patient reported outcomes (PROs), including quality of life measures, and validate glycemic measures that may serve as outcomes in clinical trials to improve glucose management in T1D.
The mission of the American Society for Hematology, the world's largest professional organization dedicated to the causes and treatment of blood disorders, is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and immunologic, hemostatic and vascular systems through the promotion of research, clinical care, education, training, and advocacy in hematology.
To that end, ASH is accepting proposals from hematologists whose research would not otherwise be accomplished due to cuts in NIH funding. Established in January 2013, the long-term goal of the program is to help sustain recipients' research and contribute to their retention in hematology investigation.
The Bridge Grants program will provide at least thirty one-year awards annually, in the amount of $150,000 each, to ASH members who applied for an NIH R01 grant or equivalent but were denied funding due to budget cuts. Grants will support projects in basic, translational, patient-oriented, or outcomes-based research.
This Funding Opportunity Announcement (FOA) seeks applications that propose to develop and test T4 implementation strategies to identify facilitators and overcome barriers in the adaptation, integration, scale-up, and sustainability of proven-effective interventions and guidelines for preventing and/or managing heart, lung, and blood diseases and/or sleep disorders (HLBS conditions). The proposed implementation strategies must be adaptable and responsive to community needs and contexts, and must account for cultural and organizational factors. For purposes of this FOA, T4 Implementation Research is defined as research to identify strategies to enhance sustainable uptake of proven-effective interventions into routine clinical practice.
This Funding Opportunity Announcement (FOA) seeks applications for the design and development of technologies to monitor health or deliver care in a real-time, accessible, effective, and minimally obtrusive way for older adults with a chronic heart, lung, blood, or sleep (HLBS) condition. These technologies may be novel sensor or monitoring systems, home-use point-of-care devices, home or mobile therapy or rehabilitation tools, or information systems and should have the goal of fostering healthy and independent living for aging adults with HLBS conditions. The development of such technologies should incorporate specific human factors for aging adults including disabilities, mild impairments, as well as chronic HLBS conditions. Technology usability for these populations must be incorporated early in the development of the design. Usability considerations include but are not limited to patient-facing displays, hearing and visual impairments, tactile limitations, literacy, and design preferences between men and women. These improvements in technology design could yield more accurate and earlier detection of changes that may interfere with healthy and independent living for older adults.
This Funding Opportunity Announcement (FOA) encourages applications from institutions/organizations proposing research on the use of current and emerging technologies for monitoring of blood glucose levels to capture the relationship between blood glucose excursions, perception of wellbeing, and cognitive status in people with type 1 diabetes (T1D). This information will inform the design of more effective interventions that may improve patient reported outcomes (PROs), including quality of life measures, and validate glycemic measures that may serve as outcomes in clinical trials to improve glucose management in T1D.
Group items tagged 
